Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $36.00. Protect Your Portfolio ...

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

Discover key earnings insights from Supernus Pharmaceuticals Q1 2025 call, highlighting 26% core product growth, ONAPGO launch, and robust strategic focus.

President and CEO of Supernus. "In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's ...

Professor of Psychiatry and Molecular Medicine, Department of Psychiatry; Hofstra North Shore Long Island School of Medicine, Hempstead, New York; Medical Director, Recognition and Prevention ...

Supernus Pharmaceuticals Inc. (SUPN) reported its first-quarter 2025 earnings on May 6, revealing a net loss that fell short of analyst expectations. The company posted a GAAP net loss per share of $0 ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported a loss of $11.8 million in its first quarter. The Rockville, Maryland-based company said it ...

The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...